Kagocel Tablets for colds and flu, 12 mg, 20 pcs

Release form

Tablets, round, biconvex, cream-colored, interspersed.

pharmachologic effect

The main mechanism of action of Kagocel is the ability to induce the production of interferons. Kagocel causes the formation in the human body of the so-called late interferons, which are a mixture of α and β interferons with high antiviral activity. Kagocel causes the production of interferons in almost all populations of cells participating in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel is taken orally, the titer of interferons in the blood serum reaches its maximum values ​​after 48 hours. The body's interferon response to the introduction of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream.The dynamics of the accumulation of interferons in the intestine when ingested Kagocel does not coincide with the dynamics of the titers of circulating interferons. In the blood serum, the production of interferons reaches high values ​​only 48 hours after taking Kagocel, while in the intestine the maximum production of interferons is noted already after 4 hours.

Kagocel, when administered in therapeutic doses, is non-toxic, does not accumulate in the body.

The drug does not possess mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.

The greatest efficiency in the treatment of Kagocel is achieved when it is administered no later than the 4th day from the onset of acute infection.

For prophylactic purposes, the drug can be used at any time, including immediately after contact with the infectious agent.

Pharmacokinetics

24 hours after its introduction into the body, Kagocel accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentration is observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel in the brain is explained by the high molecular weight of the drug, which makes it difficult for its penetration through the blood-brain barrier. In blood plasma, the drug is mainly in a bound form.

With daily repeated administration of Kagocel, the volume of distribution varies widely in all the studied organs.

The accumulation of the drug in the spleen and lymph nodes is especially pronounced.

When taken orally, about 20% of the administered dose of the drug enters the general bloodstream.

The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%.

The unbound part of the drug is about 16%.

Excretion: the drug is excreted from the body mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% through the kidneys.

The drug was not found in the exhaled air.

Indications

Kagocel is used in adults and children aged 3 years and older as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

Contraindications

- Pregnancy and lactation period

- Age up to 3 years

- Hypersensitivity to drug components

- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Application during pregnancy and lactation

Due to the lack of the necessary clinical data, Kagocel is not recommended to be taken during pregnancy and lactation.

special instructions

To achieve a therapeutic effect, Kagocel should be taken no later than the fourth day from the onset of the disease.

Structure

Active substance:

Kagocel 12 mg.

Excipients: potato starch - 10mg, calcium stearate - 0.65mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - until a tablet weighing 100 mg is obtained.

Method of administration and dosage

Inside, regardless of food intake.

For the treatment of influenza and SARS, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day.

In total, the course - 18 tablets, course duration - 4 days.

Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days - 2 tablets once a day, a break for 5 days, then repeat the cycle.

The duration of the preventive course is from one week to several months.

For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days.

A total of 30 tablets per course, the duration of the course is 5 days.

For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time a day.

In total, the course - 6 tablets, course duration - 4 days.

For the treatment of influenza and acute respiratory viral infections, children aged 6 years and older are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day.

In total for the course - 10 tablets, the duration of the course - 4 days.

Prevention of influenza and ARVI in children aged 3 years and older is carried out in 7-day cycles: two days - 1 tablet once a day, 5 days off, then repeat the cycle.

The duration of the preventive course is from one week to several months.

Side effects

The development of allergic reactions is possible.

If any of the side effects indicated in the instructions are aggravated, or if you notice any other side effects not listed in the instructions, inform your doctor.

Drug interactions

Kagocel combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).

Overdose

In case of an accidental overdose, it is recommended to prescribe an abundant drink, induce vomiting.

Storage conditions

In a dark place at a temperature not exceeding 25 C.

Keep out of the reach of children.

Shelf life

4 years.

After the expiry date indicated on the package, the drug should not be used.

Dosage

12 mg

Structure

Active substance: Kagocel 12 mg Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) - until a tablet weighing 100 mg is obtained.

Indications

Kagocel is used in adults and children aged 3 years and older as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

INN / Active ingredient

Kagocel

Contraindications

Pregnancy and lactation

- Age up to 3 years

- Hypersensitivity to drug components

- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Specifications

Category

Antiviral

,

Antimicrobial agents

Scope of the medicinal product

General

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

twenty

Scope of application

Virology

Vacation conditions

Without recipe

Brand name

Nearmedic Pharma LLC

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antiviral agent

Anatomical and therapeutic characteristics

J05AX Other antiviral drugs

Dosage form

Pills

Packaging

Cardboard box

The target audience

Children

Dosage (volume) of the substance in the preparation

1 tablet contains: Kagocel 12 mg

Expiration date in days

1460

Package weight, g

twenty

Mode of application

:

Inside, regardless of the meal. < br> For the treatment of influenza and SARS, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. In total for the course - 18 tablets, the duration of the course - 4 days. < br> Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days - 2 tablets once a day, 5 days break, then repeat the cycle. The duration of the prophylactic course is from one week to several months. < br> For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. In total for the course - 30 tablets, the duration of the course - 5 days. For the treatment of influenza and ARVI, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one at a time tablet once a day. In total for the course - 6 tablets,course duration - 4 days. For the treatment of influenza and acute respiratory viral infections, children aged 6 years and older are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. In total for the course - 10 tablets, course duration - 4 days. < br> Prevention of influenza and ARVI in children aged 3 years and older is carried out in 7-day cycles: two days - 1 tablet 1 time per day, 5 days break, then the cycle repeat. The duration of the preventive course is from one week to several months.two days - 1 tablet 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.two days - 1 tablet 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.

Information on technical characteristics, delivery set, country of manufacture